JP2024500250A5 - - Google Patents
Info
- Publication number
- JP2024500250A5 JP2024500250A5 JP2023560254A JP2023560254A JP2024500250A5 JP 2024500250 A5 JP2024500250 A5 JP 2024500250A5 JP 2023560254 A JP2023560254 A JP 2023560254A JP 2023560254 A JP2023560254 A JP 2023560254A JP 2024500250 A5 JP2024500250 A5 JP 2024500250A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- dsg2
- domain
- isolated polypeptide
- extracellular
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063125583P | 2020-12-15 | 2020-12-15 | |
| US63/125,583 | 2020-12-15 | ||
| US202163274715P | 2021-11-02 | 2021-11-02 | |
| US63/274,715 | 2021-11-02 | ||
| PCT/US2021/063433 WO2022132854A1 (en) | 2020-12-15 | 2021-12-15 | Dsg2 compositions and methods for the treatment of covid-19 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024500250A JP2024500250A (ja) | 2024-01-05 |
| JP2024500250A5 true JP2024500250A5 (enExample) | 2024-11-29 |
Family
ID=79425717
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023560254A Pending JP2024500250A (ja) | 2020-12-15 | 2021-12-15 | Ｃｏｖｉｄ－１９の治療のためのｄｓｇ２組成物及び方法 |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP4263588A1 (enExample) |
| JP (1) | JP2024500250A (enExample) |
| KR (1) | KR20230120141A (enExample) |
| AU (1) | AU2021400845A1 (enExample) |
| CA (1) | CA3202364A1 (enExample) |
| IL (1) | IL303444A (enExample) |
| MX (1) | MX2023006704A (enExample) |
| TW (1) | TW202237634A (enExample) |
| WO (1) | WO2022132854A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2024005327A (es) * | 2021-11-02 | 2024-05-21 | Arvada Therapeutics Inc | Composiciones y metodos de dsg2. |
| CN116458893A (zh) * | 2023-04-19 | 2023-07-21 | 电子科技大学 | 一种covid-19后心肌缺血的早期筛查方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100316347B1 (ko) | 1998-09-15 | 2002-08-27 | 한미약품(주) | 대장균엔테로톡신ⅱ신호펩티드의변형체와인체성장호르몬의융합단백질을발현하는재조합미생물및그를이용한인체성장호르몬의제조방법 |
| DE10057397A1 (de) | 2000-11-18 | 2002-05-23 | Hella Kg Hueck & Co | Vorrichtung zur Ölstandsmessung |
| US20100303723A1 (en) * | 2006-11-20 | 2010-12-02 | Massachusetts Institute Of Technology | Drug delivery systems using fc fragments |
| EP3568697B1 (en) * | 2017-01-13 | 2022-06-29 | The Hospital for Sick Children | Method for diagnosis of arrhythmogenic right ventricular cardiomyopathy |
-
2021
- 2021-12-15 CA CA3202364A patent/CA3202364A1/en active Pending
- 2021-12-15 KR KR1020237024240A patent/KR20230120141A/ko active Pending
- 2021-12-15 WO PCT/US2021/063433 patent/WO2022132854A1/en not_active Ceased
- 2021-12-15 EP EP21841114.8A patent/EP4263588A1/en active Pending
- 2021-12-15 AU AU2021400845A patent/AU2021400845A1/en active Pending
- 2021-12-15 JP JP2023560254A patent/JP2024500250A/ja active Pending
- 2021-12-15 TW TW110146991A patent/TW202237634A/zh unknown
- 2021-12-15 IL IL303444A patent/IL303444A/en unknown
- 2021-12-15 MX MX2023006704A patent/MX2023006704A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ko et al. | An Fc variant with two mutations confers prolonged serum half-life and enhanced effector functions on IgG antibodies | |
| US12497462B2 (en) | Anti-CD26 proteins and uses thereof | |
| JP6954842B2 (ja) | 増強された活性を有する抗体及びその改変方法 | |
| ES3009440T3 (en) | Anti human annexin a1 antibody | |
| SI2802606T1 (en) | Improves the transfer of healing molecules through the hematoencephalic barrier | |
| US20230293647A1 (en) | Polypeptide | |
| BR112019016104A2 (pt) | composição farmacêutica de baixo ph compreendendo construtos de anticorpo que empregam células t | |
| US10745466B2 (en) | Type III secretion system targeting molecules | |
| CN110662768A (zh) | 治疗性抗cd40配体抗体 | |
| CN105492461B (zh) | 结合人类补体因子c2的结合分子及其应用 | |
| CA2824805A1 (en) | Il-27 antagonists for treating inflammatory diseases | |
| WO2021047559A1 (zh) | 一种断裂型内含肽、使用其的重组多肽的制备方法 | |
| JP2020536495A (ja) | 抗ｌａｇ−３抗体及びその使用 | |
| JP2021518132A5 (enExample) | ||
| CA3134224A1 (en) | Composition for preventing or treating brain and nervous system disease | |
| JP2025515304A (ja) | Ｓｉｇｌｅｃ－８結合タンパク質及びその使用方法 | |
| KR20250057830A (ko) | 항-인간 보체 c5 항체 및 이의 융합 단백질 | |
| JP2025506341A5 (enExample) | ||
| CA3097253A1 (en) | Antibodies targeting glycoprotein vi | |
| JP2025517120A5 (enExample) | ||
| CN106573975A (zh) | 抗il4‑il13双特异性抗体 | |
| JP2024540220A5 (enExample) | ||
| KR102725210B1 (ko) | 안정화된 Ace2 변이체, 이를 이용한 Ace2-Fc 융합단백질 및 COVID-19 예방 또는 치료용 약학 조성물 | |
| CN116528899A (zh) | 抗EphA4抗体 | |
| JP2021526833A5 (enExample) |